Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II tria

Publication Type:

Journal Article


Head & neck, Volume 32, Issue 2, p.221-8 (2010)


Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Cisplatin, Disease-Free Survival, Dose Fractionation, Female, Fluorouracil, Head and Neck Neoplasms, Humans, Male, Middle Aged, Radiotherapy, Adjuvant, Taxoids


In an effort to optimize nonoperative therapy in patients with locoregionally advanced head and neck squamous cell cancer, the Southwest Oncology Group conducted a phase II trial combining 3-drug taxane-containing induction chemotherapy with accelerated fractionation/concomitant boost radiation and concomitant single-agent cisplatin.